source
- Tempus to acquire cancer test maker Personalis for $1.5BTempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.BioPharma Dive · 10d ago↗ source
- Tempus to buy cancer test-maker Personalis for $1.5BTempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.BioPharma Dive · 10d ago↗ source
- Pain drugmaker Latigo outlines plans to go publicThe Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.BioPharma Dive · 10d ago↗ source